These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23256738)

  • 1. Recent progress towards development of a Shigella vaccine.
    Camacho AI; Irache JM; Gamazo C
    Expert Rev Vaccines; 2013 Jan; 12(1):43-55. PubMed ID: 23256738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
    Levine MM; Kotloff KL; Barry EM; Pasetti MF; Sztein MB
    Nat Rev Microbiol; 2007 Jul; 5(7):540-53. PubMed ID: 17558427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.
    Gaston JS; Inman RD; Ryan ET; Venkatesan MM; Barry EM; Hale TL; Bourgeois AL; Walker RI
    Vaccine; 2009 Sep; 27(40):5432-4. PubMed ID: 19643213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated and subunit vaccines to prevent shigellosis.
    Kaminski RW; Oaks EV
    Expert Rev Vaccines; 2009 Dec; 8(12):1693-704. PubMed ID: 19943764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children.
    Walker RI
    Vaccine; 2015 Feb; 33(8):954-65. PubMed ID: 25482842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shigella vaccine development: prospective animal models and current status.
    Kim YJ; Yeo SG; Park JH; Ko HJ
    Curr Pharm Biotechnol; 2013; 14(10):903-12. PubMed ID: 24372251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies.
    Camacho AI; Souza-Rebouças J; Irache JM; Gamazo C
    Methods; 2013 May; 60(3):264-8. PubMed ID: 23046911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live-attenuated Shigella vaccines.
    Venkatesan MM; Ranallo RT
    Expert Rev Vaccines; 2006 Oct; 5(5):669-86. PubMed ID: 17181440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current aspects of Shigella pathogenesis.
    Torres AG
    Rev Latinoam Microbiol; 2004; 46(3-4):89-97. PubMed ID: 17061529
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Lu T; Das S; Howlader DR; Picking WD; Picking WL
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.
    Kim JO; Rho S; Kim SH; Kim H; Song HJ; Kim EJ; Kim RY; Kim EH; Sinha A; Dey A; Yang JS; Song MK; Nandy RK; Czerkinsky C; Kim DW
    Clin Vaccine Immunol; 2015 Apr; 22(4):381-8. PubMed ID: 25651919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shigellosis.
    Niyogi SK
    J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and pitfalls in Shigella vaccine research.
    Barry EM; Pasetti MF; Sztein MB; Fasano A; Kotloff KL; Levine MM
    Nat Rev Gastroenterol Hepatol; 2013 Apr; 10(4):245-55. PubMed ID: 23419287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D; Kaminski R; Cantrell J; Nelson M; Porter C; Baqar S; Williams C; Arora R; Saunders J; Ananthakrishnan M; Sanders J; Zaucha G; Turbyfill R; Oaks E
    Vaccine; 2010 Aug; 28(37):6076-85. PubMed ID: 20619378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
    Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
    mSphere; 2018; 3(2):. PubMed ID: 29600284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel
    Ndungo E; Randall A; Hazen TH; Kania DA; Trappl-Kimmons K; Liang X; Barry EM; Kotloff KL; Chakraborty S; Mani S; Rasko DA; Pasetti MF
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30068560
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response.
    Mukhopadhaya A; Mahalanabis D; Chakrabarti MK
    Vaccine; 2006 Aug; 24(33-34):6028-36. PubMed ID: 16765491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.
    Pahil S; Taneja N; Ansari HR; Raghava GPS
    PLoS One; 2017; 12(8):e0180505. PubMed ID: 28767653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-protection provided by live Shigella mutants lacking major antigens.
    Szijártó V; Hunyadi-Gulyás E; Emődy L; Pál T; Nagy G
    Int J Med Microbiol; 2013 May; 303(4):167-75. PubMed ID: 23567193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.